Isoniazid
Isoniazid (CAS: 54-85-3) is a white to almost white crystalline antitubercular active ingredient and one of the most important first-line medicines for tuberculosis treatment. It is the hydrazide of isonicotinic acid and acts as a prodrug, activated by bacterial catalase-peroxidase to inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. As a bulk API it is formulated into tablets and fixed-dose combinations for tuberculosis therapy worldwide. The compound is freely soluble in water and stable as a dry powder, supporting straightforward formulation and long shelf life. Buyers procure it for anti-TB pharmaceutical production where pharmacopoeial compliance (IP/BP/USP/EP) and consistent quality are required.
• Anti-TB API: the active ingredient in first-line tuberculosis tablets and fixed-dose combination therapies.
• Mechanism: a prodrug activated by bacterial enzymes that blocks mycolic acid synthesis in M. tuberculosis.
• Formulation friendly: freely water-soluble and stable as a dry powder, supporting tablets and oral dosage forms.
• Pharmacopoeial: an established monograph substance in the IP/BP/USP/EP compendia.
Product Name: Isoniazid
For global customers, we provide complete technical documentation to support product evaluation, regulatory compliance and safe handling during transportation and application.